ASCO News In Brief: Roche Roferon-A
Executive Summary
Roche Roferon-A: Helsinki University Hospital Phase III study of recombinant interferon alfa-2a (IFN) with vinblastine (VLB) versus vinblastine alone in 160 patients with advanced renal cell carcinoma shows a seven-month increase in median survival for the IFN/VLB arm (15.8 months v. 8.8 months). Objective response rates were 16% for IFN/VLB and 2.5% for VLB alone. Median time to progression was 3 months in the IFN/VLB arm and 2.1 months in the VLB arm. Reversible granulocytopenia was experienced by 12 of 79 patients in the IFN/VLB arm...